Feb 13 2017
Corindus Vascular Robotics, Inc., a leading developer of precision vascular robotics, announced today that the first commercial procedures have been performed using its CorPath GRX System following the company’s recent 510(k) clearance from the U.S. Food and Drug Administration (FDA). In early February, NewYork-Presbyterian, UC San Diego Health, and University of Virginia Health System used the CorPath GRX System to perform robotic-assisted PCI procedures. Corindus began limited installations of the CorPath GRX System in January 2017 with plans for a full commercial launch in late February.
Hospital programs provided positive feedback on their initial experience with the CorPath GRX System.
Manish Parikh, MD, Associate Director of the Cardiac Catheterization Laboratory at NewYork-Presbyterian, stated, "We are proud to be among the group of premier hospitals that performed the first cases in the world using the new CorPath GRX System. The enhancements provided by CorPath GRX represent a dramatic improvement in the capabilities in robotic PCI and have the potential to provide significant improvements in patient care."
Ehtisham Mahmud, MD, Division Chief of UC San Diego Health, Cardiovascular Medicine and Medical Director, Sulpizio Cardiovascular Center, stated, "I am impressed with the additional capabilities of the new GRX System. The redesigned bedside unit, intuitive control console, and especially guide catheter control further facilitate complex PCI procedures. It also enables me to train other interventionalists and fellows in state-of-the-art robotics."
Michael Ragosta, MD, Interventional Cardiologist, stated, "The CorPath GRX System provides me with complete robotic control during complex PCI procedures. Using CorPath GRX and its radiation-shielded cockpit has enabled me to expand the number of procedures I can perform."
CorPath GRX offers enhancements to the CorPath platform by adding important key upgrades that increase precision, improve workflow, and extend the capabilities and range of procedures that can be performed robotically. The unique Active Guide Management feature allows interventional cardiologists to control the guide catheter, which was not possible with the first generation technology. Physicians now have independent and simultaneous robotic control of guide catheters, guidewires, and balloon/stent catheters, with one-millimeter advancement, from the cockpit console. This precise positioning that allows physicians to adjust guide catheters during PCI procedures may expand the use of the CorPath GRX System to more complex cases. CorPath GRX also features a completely redesigned bedside unit featuring an extended reach arm and touchscreen display to streamline workflow.
"Completion of these initial CorPath GRX procedures marks an important step forward in vascular robotics," said Mark Toland, President and Chief Executive Officer of Corindus Vascular Robotics. "We are committed to continuing to develop and deliver innovative products to advance the field of cardiovascular robotics and support better patient outcomes."
Source: http://www.corindus.com/